MCCORMICK FRANK 4
4 · BridgeBio Pharma, Inc. · Filed Sep 8, 2025
Insider Transaction Report
Form 4
MCCORMICK FRANK
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-05$11.92/sh+74,000$882,080→ 157,275 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-05−74,000→ 84,814 totalExercise: $11.92Exp: 2033-02-20→ Common Stock (74,000 underlying) - Sale
Common Stock
2025-09-05$53.16/sh−74,000$3,933,544→ 83,275 total
Holdings
- 879,979(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.